[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-st-segment-elevation-acute-coronary-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-st-segment-elevation-acute-coronary-syndrome":154},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,70,100,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100612335","pre-hospital-triage-of-patients-at-intermediate-and-high-risk-for-acs-100612335",false,"NCT07252245","Pre Hospital Triage of Patients at Intermediate and High Risk for ACS","Pre Hospital Triage of Patients at Intermediate and High Risk for ACS: ARTICA-2 Trial","ARTICA-2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* All out-of-hospital patients with chest pain or symptoms suggestive of ACS with an indication for transfer to the (cardiac) emergency department to evaluate and rule out ACS\n* Modified HEAR(T) score ≥ 4\n* The patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.\n\nExclusion Criteria:\n\n* Electrocardiographic ST-segment elevation (STEMI)\n* Patients with confirmed myocardial infarction, PCI or CABG \\\u003C14 days prior to inclu-sion\n* Patients presenting an obvious non-cardiac cause for the chest complaints who need evaluation at an emergency department, e.g. trauma, pneumothorax, sepsis, etc.\n* Patients in comatose state, defined as an EMV \\\u003C8\n* Patients with known cognitive impairment\n* Pregnancy or intention to become pregnant during the course of the study\n* Patients presenting with cardiogenic shock, defined as: systolic blood pressure \\\u003C90mmHg and heart rate \\>100 and peripheral oxygen saturation \\\u003C90% (without oxygen administration)\n* Patients presenting with syncope\n* Patients presenting with signs of heart failure\n* Patients presenting with second or third degree atrioventricular block\n* Patients without known supraventricular tachycardia i.e. unknown atrial fibrillation (known atrial fibrillation with adequate rate control can be included)\n* Patients with known end-stage renal disease (dialysis and\u002For GFR \\\u003C 30 ml\u002Fmin)\n* Patients without a pre-hospital 12-lead ECG performed or available\n* Patients suspicious of aortic dissection or pulmonary embolism\n* Communication issues with patient\u002Flanguage barrier\n* Any significant medical or mental condition, which in the Investigator's opinion may interfere with the patient's optimal participation in the study","ALL","18 Years",{"count":20,"type":21},1048,"ESTIMATED","INTERVENTIONAL",[24],"NA","RESEARCH QUESTION: Is a treatment strategy that includes direct referral to a PCI center for intermediate to high-risk patients with non-ST elevation acute coronary syndrome (NSTE-ACS), both cost-effective and non-inferior for major adverse cardiac events (MACE)? HYPOTHESIS: Prehospital triage with the modified \\[History-ECG-Age-Risk factors\\] (HEAR) score and a high sensitivity (hs) point-of-care troponin (POCT) leads to a faster diagnosis of ACS, faster time to coronary angiography (CAG) and\u002For treatment with PCI, shorter length of stay, quicker availability of ambulances and more satisfaction and quality of life of patients. STUDY DESIGN: Randomized clinical trial. STUDY POPULATION: Patients ≥18 years with an intermediate to high risk for NSTE -ACS (defined as a modified HEAR score ≥ 4) INTERVENTION: applying modified HEAR score and hs POCT to identify patients for direct rule out (very low risk), transfer to the nearest hospital for rapid rule-out and\u002For fast-track diagnosis by CT coronary imaging (intermediate risk) or direct referral to a PCI center for CAG (high risk).\n\nUSUAL CARE\u002FCOMPARISON: Assessment of ACS at the nearest hospital. In case PCI is scheduled: transfer to nearest PCI center.\n\nOUTCOME MEASURES: primary endpoints: healthcare costs and non-inferiority for MACE (all cause death, confirmed ACS, re ACS, and unplanned PCI or CABG) at 30 days. Secondary: MACE after rule out ACS at 30 days, Quality of life (EQ5D5L) and cost-effectiveness at 12 months.\n\nSAMPLE SIZE: 1048 patients. COST-EFFECTIVENESS ANALYSIS \u002F BIA: It is expected that the intervention group will reduce healthcare costs and potentially improve health-related quality of life in this target population. Cost-effectiveness will be expressed as cost per QALY gained. We assume a large potential saving more than € 37 million if 100% implemented. TIME SCHEDULE: 48 months; 36 month inclusion, follow-up 12 months",[27],"Non ST Segment Elevation Acute Coronary Syndrome",[29,30,31,32,33,34],"HEART score","NSTE-ACS","Pre-hospital triage","high risk ACS","intermediate risk ACS","point-of-care troponin","NOT_YET_RECRUITING","2025-11-18",{"date":38,"type":39},"2025-11-26","ACTUAL",{"date":41,"type":21},"2026-01-01",{"date":43,"type":21},"2030-02-01",{"name":45,"class":46},"Cyril Camaro","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":47},"100531278","mcg-for-identification-of-myocardial-ischemia-in-suspected-nste-acs-patients-100531278","NCT06197724","MCG for Identification of Myocardial Ischemia in Suspected NSTE-ACS Patients","Magnetocardiography as an Innovative Diagnostic Tool for Early and Accurate Identification of Myocardial Ischemia in Suspected NSTE-ACS Patients","Inclusion Criteria:\n\n1. Age 18 years or older;\n2. Patients with symptoms of myocardial ischemia such as angina who are suspected to NSTE-ACS and proposed to undergo CAG or coronary CTA;\n3. Signed informed consent.\n\nExclusion Criteria:\n\n1. Patients with ST-elevation myocardial infarction (STEMI);\n2. Patients with Non-ischemic dilated cardiomyopathy, or hypertrophic cardiomyopathy, or moderate or severe valvular disease;\n3. Patients with Hemodynamic instability (systolic blood pressure\\\u003C90 mmHg, or who requires vasoactive drugs), or patients with tachyarrhythmia, Ⅱ degree atrioventricular block and above that have not returned to normal;\n4. Patients who have severe renal abnormality with eGFR \\\u003C30 ml\u002Fmin, or patients who are on dialysis;\n5. Patients with malignant tumors with predicted survival of less than 1 year;\n6. Pregnant or breastfeeding women;\n7. Patients who are unable to enter the MCG device, who are unable to perform MCG examination due to interference from metal implants or other reasons, or who are deemed by the investigators to be unsuitable for enrollment.",{"count":56,"type":21},14090,"OBSERVATIONAL","The goal of this multi-center observational study is to learn about the effectiveness of magnetocardiography in rapid and accurate identification of ischemia in patients with suspected NSTE-ACS.",[27],"RECRUITING","2025-09-23",{"date":63,"type":39},"2025-09-29",{"date":65,"type":39},"2024-01-02",{"date":67,"type":21},"2026-01-31",{"name":69,"class":46},"Qilu Hospital of Shandong University",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":47},"100569529","supplementation-with-beetroot-juice-to-prevent-contrast-associated-nephropathy-during-hospitalization-for-acute-coronary-syndrome-without-st-elevation-100569529","NCT06695429","Supplementation With Beetroot Juice to Prevent Contrast Associated Nephropathy During Hospitalization for Acute Coronary Syndrome Without ST Elevation","Suplementación Con Zumo de REmolacha Para Prevenir la Nefropatía Asociada a Contraste Durante la hospitalización Por Síndrome Coronario Agudo Sin elevación Del ST","RENACS","Inclusion Criteria:\n\n* Diagnosis of Acute Coronary Syndrome without persistent ST segment elevation, with recommendation for invasive management according to the actual Clinical practice guidelines\n* At least moderate or high risk of nephropathy associated with iodinated contrast (Mehran score (without including contrast volume) ≥ 6).\n\nExclusion Criteria:\n\n* \\\u003C18 years old or without capacity to give consent.\n* Refusal to participate in the study.\n* Known hypersensitivity to beetroot or any of its allergens.\n* Pregnant.\n* Inability to take food orally\n* Serious illnesses (not related to ACS or kidney failure), which limits their life expectancy to a period predictably less than 1 year.\n* On dialysis or predialysis at the time of inclusion.\n* ACS with persistent ST segment elevation before inclusion.\n* Shock or inotrope dependence at the time of inclusion\n* PCI already performed before inclusion.\n* Patients receiving intravenous nitroglycerin for \\> 1 hour before inclusion",{"count":79,"type":21},130,[24],"The goal of this study is to compare the possible beneficial effect of beetroot juice supplementation versus the usual management during hospitalization to prevent contrast-induced nephropathy after cardiac catheterizations.\n\nThe study includes patients diagnosed with non-ST elevation acute coronary syndrome with a possible indication for catheterism and high risk of kidney injury related to iodinated contrast.\n\nThe intervention group will drink 500 mL (2 glasses daily, at breakfast and dinner) of beetroot juice added to the usual diet for 7 days or until hospital discharge and will receive the recommendation to maintain a diet rich in inorganic nitrates. The control group will receive the usual diet and recommendations. In both cases, other therapies will be prescribed to prevent contrast-induced nephropathy (hydration and statins) if there is no contraindication.\n\nOur hypothesis is that a compound present in beetroot juice, inorganic nitrates, can prevent the deterioration of kidney function related to contrast due to its vasodilatory effect, in addition to improving the subsequent prognosis of coronary heart disease due to its anti-inflammatory and antiproliferative effects, protector of the endothelium and inhibitor of platelet aggregation. Beetroot juice could also be beneficial in this context due to the antioxidant effect of the betalains it contains.",[27,83],"Contrast Induced Nephropathy",[85,86,87,88,89,90],"Beetroot juice","Inorganic nitrates","Contrast induced nephropathy","Non ST elevation acute coronary syndrome","Percutaneous coronary intervention","Contrast","2025-05-14",{"date":93,"type":39},"2025-05-18",{"date":95,"type":39},"2024-10-07",{"date":97,"type":21},"2027-09-30",{"name":99,"class":46},"Hospital General Universitario Santa Lucia",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":110,"studyType":57,"phases":4,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":47},"100535734","angio-based-final-functional-effect-of-pci-100535734","NCT06255678","Angio-based Final Functional Effect of PCI","Angio-based Final Functional Effect of PCI (AFFE PCI): a Prospective Multi-center Study of Post-PCI vFFR Impact on Clinical Outcomes and Residual Angina","AFFE-PCI","Inclusion Criteria:\n\n* Percutaneous coronary intervention (PCI) for chronic coronary syndromes (CCS) or acute coronary syndromes (ACS)\n* Adequate quality of angiogram enabling vFFR analysis (available two angiographic views with ≥30° differences in rotation\u002Fangulation, the possibility of vessel contour selection, proper quality of the images, vessels without severe overlapping, tortuosity, foreshortening and poor vessel opacification)\n* Age \\>18 years\n* The patient's written informed consent has been obtained before the procedure\n\nExclusion Criteria:\n\n* Cardiogenic shock, pulmonary oedema\n* Severe hemodynamical instability\n* Prior coronary artery bypass grafting (CABG)\n* Active bleeding\n* Acute and chronic inflammatory conditions\n* Acute mechanical complications of myocardial infarction\n* Congenital heart disease\n* Heart transplantation\n* Non-cardiac comorbidities with a life expectancy of less than 1 year",{"count":109,"type":21},2005,"2 Years","Fractional flow reserve (FFR) has revolutionized the diagnosis and treatment of coronary artery disease (CAD), and more recently, post percutaneous coronary intervention (post-PCI) FFR has emerged as an independent predictor of cardiovascular events, enabling the identification of cases requiring additional optimization of the implanted stent. Modern technologies allow less invasive alternatives to traditional FFR measurement - angiography-based vessel fractional flow reserve (vFFR) and derivative ΔvFFR, which is calculated by a difference between the post-PCI vFFR and pre-PCI vFFR. In large clinical studies, the good accuracy between vFFR and FFR - measured before and after PCI - has been confirmed. However, insufficient data is available about the value of post-vFFR and ΔvFFR as prognostic values and indicators of patient health.\n\nThis is a prospective multicenter register study analyzing the association between the value of ΔvFFR, vFFR after PCI and adverse clinical outcomes, residual angina and quality of life using the validated Seattle Angina Questionnaire (SAQ) and EuroQol 5-level 5-dimensional questionnaire (EQ-5D-5L). Patients undergoing PCI for chronic coronary syndromes (CCS), non-ST-segment elevation acute coronary syndromes (NST-ACS) or ST-Segment Elevation Myocardial Infarction (STEMI) will be enrolled in this study.",[113,27,114],"Acute Coronary Syndrome","Chronic Coronary Syndrome",[116,117,118,119,120,121],"vFFR","ACS","NST-ACS","Angiography-based FFR","Quality of life","Residual angina","2024-02-02",{"date":124,"type":39},"2024-02-13",{"date":126,"type":39},"2023-07-03",{"date":128,"type":21},"2027-01-01",{"name":130,"class":46},"Medical University of Warsaw",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":4},"100523532","early-initiation-of-tafolecimab-for-patients-with-acute-coronary-syndromeundergoing-percutaneous-coronary-intervention-in-chinese-population-100523532","NCT06096909","Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population","Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population (EMPACT): A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 18 to 75 years;\n* clinical diagnosis with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) ;\n* undergoing PCI\n* baseline LDL-C 1.8 mmol\u002FL 3.4 mmol\u002FL note: NSTE-ACS includes non-ST-elevation myocardial infarction and unstable angina.\n\nExclusion Criteria:\n\n* Severe heart failure (Killip III or IV) or cardiogenic shock;\n* Previous hemorrhagic cerebrovascular disease history;\n* Uncontrolled or recurrent arrhythmic events;\n* poorly controlled hypertension;\n* Severe hepatic and renal insufficiency (ALT\u002FAST\\> 3 times upper limit of normal, eGFR\\\u003C30 ml\u002Fkg\u002F1.73m2, or ongoing dialysis) or creatine kinase elevation\\>5 times upper limit of normal\n* malignant tumor;\n* Intolerance to statins or cholesterol absorption inhibitors;\n* Intolerance to injections;\n* Life expectancy \\\u003C1 year;\n* poor compliance.","75 Years",{"count":140,"type":21},3684,[24],"For patients with ACS undergoing PCI, intensive lipid-lowering including PCSK9 monoclonal antibody should be started as soon as possible, that is, lower LDL-C level should be achieved as soon as possible. Compared with conventional lipid-lowering regimen, it is expected that the occurrence of major adverse cardiovascular events can still be reduced after drug discontinuation. Therefore, the optimization strategy of \"for patients with ACS undergoing PCI, intensive lipid-lowering with PCSK9 monoclonal antibody can be started as soon as possible\" is proposed.",[113,27],"2023-10-20",{"date":146,"type":39},"2023-10-24",{"date":148,"type":21},"2023-11-01",{"date":150,"type":21},"2027-11-01",{"name":152,"class":153},"China National Center for Cardiovascular Diseases","OTHER_GOV","Non-ST Segment Elevation Acute Coronary Syndrome"]